Trade IMVT stock anytime, 24x5 in Singapore
Regulated by
Monetary Authority of Singapore (MAS)
Trusted by
400,000+ users
Immunovant, Inc. (IMVT) is trading at US$33.25, down 1.10% today as of Oct 5, 16:00 EDT. The company has a market capitalisation of US$9.16B. Over the past 52 weeks, IMVT has traded between US$15.95 and US$45.42. On Syfe you can trade IMVT with $0 commission and add it to your watchlist.
| Previous close | US$33.62 |
|---|---|
| Market cap | US$9.16B |
| 52-week range | US$15.95 – US$45.42 |
| Volume | 1.1M |
| Exchange | US |
Immunovant, Inc.
Immunovant, Inc. is a clinical-stage biopharmaceutical company, which focuses on enabling normal lives for patients with autoimmune diseases. It develops a novel, fully human monoclonal antibody, IMVT-1401, which selectively binds to and inhibits the neonatal fragment crystallizable receptor. The company was founded on July 6, 2018 and is headquartered in Durham, NC.
Year: 2019
Immunovant's Risk/Reward Profile Balanced After Recent Rally, UBS Says
Aug 24, 5:16 PM · MT Newswires
Immunovant, Inc. (IMVT) stock is trading at US$33.25, -1.10% from the previous close of US$33.62.
The market cap for Immunovant, Inc. (IMVT) stock is approximately US$9.16B.
The 52-week high for Immunovant, Inc. (IMVT) stock is US$45.42.
The 52-week low for Immunovant, Inc. (IMVT) stock is US$15.95.
Immunovant, Inc. (IMVT) does not currently pay a dividend.
Stay on top of IMVT
Price moves, news and earnings — straight to your inbox.
Snapshot
Popular Stocks in Singapore
